LOS ANGELES, CA -- (Marketwire) -- 02/05/10 -- BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Keryx Biopharmaceuticals (NASDAQ: KERX) was mentioned in a published article which contained an inaccurate statement regarding the design of a pending Phase III study for patients with metastatic colorectal cancer. Keryx CEO Ron Bentsur spoke to BioMedReports and has noted on record that it is estimated that approximately 50% to 60% of mCRC patients are KRAS positive, so that only this sub-group would potentially benefit
More...
More...